Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to announce that it has signed a definitive agreement to sell GPP II portfolio company, MaSTherCell Global (“MaSTherCell”), a subsidiary of Orgenesis (NASDAQ: ORGS), to Catalent Pharma Solutions, Inc. after significantly growing the business. MaSTherCell, based in Belgium and Houston, Texas, is a leading technology-focused cell and gene therapy contract development and manufacturing (“CDMO”) partner for leading biotechnology and pharmaceutical companies. GPP made a growth equity investment in MaSTherCell in June 2018 alongside Orgenesis, a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry, and SFPI-FPIM, a Belgian sovereign wealth fund.
Read the full article: Great Point Partners II Sells MaSTherCell Global to Catalent //
Source: http://gppfunds.com/news